BRCA Mutation Testing in Men With Metastatic Castration‐Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice
Asia-Pacific Journal of Clinical Oncology · 2025
DOI: 10.1111/ajco.14150 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2025. Verfasst von Arun A Azad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, BRCA1 Protein, BRCA2 Protein, Genetic Testing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Some patients with metastatic castration‐resistant prostate cancer (mCRPC) possess germline or acquired defects in the DNA damage repair (DDR) genes BRCA1 and BRCA2 . Tumors with BRCA mutations exhibit sensitivity to poly‐ADP ribose polymerase inhibitors (PARPi) such as olaparib and rucaparib. As a result, molecular diagnostic testing to identify patients with BRCA mutations eligible for the PARPi therapy has become an integral component of managing patients with mCRPC. There are practical challenges in the current molecular testing pathway in Australia that can compromise testing success. Testing success is often contingent on quality of tissue handling and laboratory processing techniques to minimize DNA degradation and suboptimal sequencing data quality. Greater adoption of best testing practices in Australia can be facilitated with education and greater awareness of expert recommendations. Here, we provide expert recommendations on how to optimize BRCA molecular diagnostic testing in patients with mCRPC. Optimization and standardization of molecular diagnostic testing will support health care providers and institutes in establishing more efficient testing pathways, enabling access to targeted therapies such as PARPi, and improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
- Faculty of Medicine, Health and Human Sciences, Macquarie University, Westmead Hospital, Westmead, Australia.
- Austin Health, Clinical Genetics Department, Heidelberg, Victoria, Australia.
- Department of Medical Oncology, Cancer Care Services, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia.
- Department of Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.
ORCID-Profile: Howard Gurney
Förderung
- AstraZeneca
Zitieren
APA
Azad, A. A., Gurney, H., Campbell, A., Goh, J. C., & Rathi, V. (2025). BRCA Mutation Testing in Men With Metastatic Castration‐Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14150
Vancouver
Azad AA, Gurney H, Campbell A, Goh JC, Rathi V. BRCA Mutation Testing in Men With Metastatic Castration‐Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice. Asia-Pacific Journal of Clinical Oncology. 2025. doi:10.1111/ajco.14150
BibTeX
@article{Azad2025,
author = {Azad, Arun A and Gurney, Howard and Campbell, Ainsley and Goh, Jeffrey C and Rathi, Vivek},
title = {BRCA Mutation Testing in Men With Metastatic Castration‐Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2025},
doi = {10.1111/ajco.14150}
}
EUVIMED